Dr. Harold Jacob was appointed a director in July 2008.
Since 1998, Dr. Jacob has served as the president of Medical Instrument Development Inc., a company which provides a range of support and consulting services to start-up and early stage companies as well as patenting its own proprietary medical devices.
Since 2011, Dr. Jacob has also served as an attending physician at Hadassah University Medical Center, where he has served as the director of the gastrointestinal endoscopy unit since September 2013.
Dr. Jacob has advised a spectrum of companies in the past and he served as a consultant and then as the Director of Medical Affairs at Given Imaging Ltd., from 1997 to 2003, a company that developed the first swallowable wireless pill camera for inspection of the intestine.
has licensed patents to a number of companies including Kimberly-Clark Corporation
Since 2014, Dr. Jacob has served as the Chief Medical Officer and a director of NanoVibronix, Inc., a medical device company using surface acoustics to prevent catheter acquired infection as well as other applications, where he served as Chief Executive Officer from 2004 to 2014.
He practiced clinical gastroenterology in New York and served as Chief of Gastroenterology at St. John's Episcopal Hospital and South Nassau Communities Hospital from 1986 to 1995, and was a Clinical Assistant Professor of Medicine at SUNY from 1983 to 1990.
Dr. Jacob founded and served as Editor in Chief of Endoscopy Review and has authored numerous publications in the field of gastroenterology.
We believe that Dr. Jacob's qualifications to serve on our Board include his years of experience in the biomed industry, his experience serving in management roles of various companies, as well as his knowledge and familiarity with gastroenterology.
The Board has determined that Michael Berelowitz, Harold Jacob
, Gerald Ostrov and Leonard Sank, are independent as defined under the rules promulgated by NASDAQ.
The members of our Audit Committee
are Leonard Sank, Harold Jacob
and Gerald Ostrov.
Harold Jacob, a director, failed to timely file a Form 4 reporting his April 14, 2014 acquisition of 700 shares of our common stock.
filed a Form 4 reporting this transaction on April 18, 2014.
also failed to timely file a Form 4 reporting a sale of an aggregate of 834 shares of our common stock on December 30, 2013.
filed a Form 4 reporting this transaction on January 29, 2014.